Since the MK2 pathway has been shown to regulate cytokine production, and we have recently suggested fibrosis-promoting activity in IBD [12,16], here, we sought to examine the impact of MK2 inhibition on PSC. This evidence concerns the gene MAPKAPK2 and inflammatory bowel disease.